Major Depressive Disorder

G Grobler
South African Journal of Psychiatry | Vol 19, No 3 | a946 | DOI: | © 2013 G Grobler | This work is licensed under CC Attribution 4.0
Submitted: 11 January 2016 | Published: 30 August 2013

About the author(s)

G Grobler,

Full Text:

PDF (147KB)


The treatment guideline draws on several international guidelines: (i)Practice Guidelines of the American Psychiatric Association (APA)for the Treatment of Patients with Major Depressive Disorder, SecondEdition;[1](ii) Clinical Guidelines for the Treatment of DepressiveDisorders by the Canadian Psychiatric Association and the CanadianNetwork for Mood and Anxiety Treatments (CANMAT);[2](iii)National Institute for Clinical Excellence (NICE) guidelines;[3](iv) RoyalAustralian and New Zealand College of Psychiatrists Clinical PracticeGuidelines Team for Depression (RANZCAP);[4](v) Texas MedicationAlgorithm Project (TMAP) Guidelines;[5](vi) World Federation ofSocieties of Biological Psychiatry (WFSBP) Treatment Guideline forUnipolar Depressive Disorder;[6]and (vii) British Association forPsychopharmacology Guidelines.[7


No related keywords in the metadata.


Total abstract views: 7494
Total article views: 3142


Crossref Citations

1. Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease
Veronica Antipova, Carsten Holzmann, Alexander Hawlitschka, Martin Witt, Andreas Wree
Toxins  vol: 13  issue: 7  first page: 505  year: 2021  
doi: 10.3390/toxins13070505